Drug intelligence / Profile preview

REMD

Development stage: Unknown
Lead developer: REMD Biotherapeutics
Modality: IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

REMD refers to a class of human monoclonal antibodies, exemplified by REMD 2.59 and REMD-477, developed by REMD Biotherapeutics. These antibodies function as competitive antagonists of the glucagon receptor (GcgR). They are being investigated for their therapeutic potential in metabolic disorders such as type 2 diabetes, type 1 diabetes, and diabetic cardiomyopathy. Their mechanism involves suppressing hepatic glucose production, improving glycemia, enhancing insulin action, and increasing AMP-activated protein kinase (AMPK)-mediated lipid oxidation, which contributes to cardioprotection.

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on REMD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REMD.

Explore the full profile